Profil
John Fry worked at Alios BioPharma, Inc. from 2011 to 2018, where he held the position of VP-Head-Early Development & Infectious Diseases from 2014 to 2018.
He then joined Aligos Therapeutics, Inc. in 2018 and worked there until 2023 as the Executive Vice President-Clinical Development.
Prior to his professional career, Mr. Fry completed his undergraduate degree at the University of Sussex.
Anciens postes connus de John Fry
Sociétés | Poste | Fin |
---|---|---|
ALIGOS THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/04/2023 |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Directeur Technique/Scientifique/R&D | 01/11/2014 |
Formation de John Fry
University of Sussex | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
ALIGOS THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Health Technology |